| INTRODUCTION
Celiac disease (CD) is an autoimmune-mediated enteropathy with tissue transglutaminase (TTG) as autoantigen 1 triggered by an abnormal immune response to wheat gluten and related cereal peptides in genetically predisposed persons. 2 The diagnosis is based on the assessment of highly variable clinical symptoms, antibody measurements, histological evaluation of intestinal biopsy samples, and response to gluten-free diet. 3 Measurement of IgA-antibodies against tissue transglutaminase (IgA-aTTG) currently represents the most sensitive and specific antibody test in the diagnosis of CD. Diagnostic sensitivity of IgA-aTTG assays after exclusion of patients with IgAdeficiency reaches almost 100%. 4 Assays for measuring the autoantibodies apply the recombinant TTG coated to plastic surfaces 5 or magnetic beads 6 to capture autoantibodies in sera.
Hemolysis (HL) is one of the most relevant pre-analytical events influencing the validity of results of laboratory diagnostics. Traditionally, Abbreviations: CD, celiac disease; CI, confidence interval; HI, hemolysis index; HL, hemolysis;
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the identification of hemolytic samples has been performed by visual inspection of the color of serum or plasma. However, free hemoglobin below 50 mg/dL is not visible and concentrations between 50
and 130 mg/dL are difficult to identify. 7 Since a couple of years, free hemoglobin is routinely quantified photometrically in parallel to most biochemical assays and a HL index (HI; 1 index point = ~1 mg free hemoglobin per 1 dL) is calculated. TTG is abundant in erythrocytes 8, 9 and released upon disruption of the membrane of red blood cells into the serum. The released erythrocytic TTG could interfere with binding of IgA-aTTG to the coated recombinant TTG. Therefore, a recent report 10 recommended that aTTG should not be determined in samples with visible HL. Furthermore, the authors showed that HL did not affect the detection of IgG-antibodies against deamidated gliadin (IgG-aDGL). The current study aims to support the interpretation of IgA-aTTG measurement in samples affected by HL.
| MATERIALS AND METHODS

| Ethics statement
The use of the serum samples for scientific purpose was approved by 
| Samples
To investigate the effect of HL on assay of IgA-aTTG at different con- 
| Spiking of serum samples with hemoglobin
To simulate different levels of HL, we generated artificial hemolysates.
For that purpose, we isolated the cellular compartment from EDTAblood by centrifugation and washed the cell pellet 3 times with 0.9% NaCl. Afterward, the cell pellet was resuspended in distilled water and frozen over night at −20°C. After thawing and rough shaking, withdrawal of blood, transport to laboratory, sample processing, storage time, and measurement of autoantibodies, spiked samples were incubated for 2 hours at room temperature prior to the measurement.
To ensure that the calculated HI is present in the spiked samples, we performed control measurements of HI in selected samples after spiking and confirmed the hemoglobin concentration (data not shown).
| Antibody assays
IgA-aTTG were measured by ELISA with assay A (cut-off ≥20 U/mL; EUROIMMUN Medizinische Labordiagnostika AG) and with assay B (Inova Diagnostics, cut-off ≥4 U/mL; Quanta Lite ® , San Diego,
USA) following the manufacturer's instructions. For measuring
IgG-aDGL, we applied an ELISA kit of EUROIMMUN Medizinische
Labordiagnostika AG (cut-off ≥25).
A decrease of the IgA-aTTG concentration by at least 10% (twofold of the mean inter-assay variation) was considered not to be caused by error of the ELISA tests but by HL.
| Hemolytic samples tested for IgA-aTTG in our children's hospital
To estimate how often the IgA-aTTG assay may be influenced by HL, we searched the LabCentre data base with anonymized patent data (i-SOLUTIONS Health GmbH, Mannheim, Germany) of our clinical routine lab for pediatric cases which were tested simultaneously for
IgA-aTTG and HI between January 2015 and December 2016 in our laboratory (baseline and follow-up).
| RESULTS
| Hemolysis influences the measurement of IgA-aTTG
We observed a significant reduction of the IgA-aTTG concentration 
× ULN (group 3)
. Applying assay B, the critical HI thresholds were 50, 100, and 200, respectively. The mean half-maximum inhibitory concentration (IC 50 ) of HI for group 1 and 2 was 290 and 620 using assay A as well as 484 and 800 applying assay B. For group 3, a maximum decrease of 25% was observed at an HI of 800 for both tests. 
| Hemolysis and false-negative IgA-aTTG results
As depicted in Figure 2 , there was one serum of group 1 with a lowpositive IgA-aTTG concentration, which showed false-negativity in both tests even at a HI between 12.5 and 25. This low level of HL is not visible. Two low-positive sera of group 1 declined below the respective cut-offs when the HI was between 100 and 300, respectively. Notably, only 2 sera of group 2 decrease below the respective thresholds after induction of HL with an HI of 800 (data not shown).
None of the sera of group 3 showed negativity even at an HI of 800.
However, IgA-aTTG was decreased below the 10 × ULN in 3 of 5 sera at a HI of 200, and in all 5 sera at a HI of 800. None of the samples in group 1, 2, and 3 reached values below the measurement range after spiking with hemolysates.
| Hemolysis does not influence detection of IgG-aDGL
We also assayed IgG-aDGL in the spiked sera. Ten of 17 sera were positive for IgG-aDGL before spiking. The concentration of IgG-aDGL was not decreased by spiking in any of the samples, irrespective of the hemoglobin concentration (Figure 3 ).
| IgA-aTTG is not depressed in two false-positive sera by spiking with hemolysates
We also spiked 2 sera with the hemolysates, which were tested initially false-positive (CD clinically and histologically excluded) with assay A.
Interestingly, both remained positive despite increasing HI applying assay A ( Figure S1A ). Only one of these sera was initially positive with assay B (Figure S1B ). Also in assay B, spiking with hemolysates did not alter the concentration of IgA-aTTG in both sera.
| Frequency of hemolytic serum samples tested for IgA-aTTG
We found 1102 sera, which were tested simultaneously for IgA-aTTG and HI within 2 years in our clinical routine lab. In 317 of the cases (28.8%), the HI was ≥25 indicating a possible interference with assays of IgA-aTTG. Assuming that HL is not able to cause a reduction from positive IgA-aTTG concentrations (>1 × ULN) to levels below the measurement range (see above), only 41 of 317 sera remained with a HI ≥25, in which the IgA-aTTG concentration might have been positive in the absence of HL. In 9 of these sera, the HI was ≥100. In 3 cases, HL seemed to have an effect on IgA-aTTG detection because
IgA-aTTG levels were between cut-off and the lower end of the detection range. The highest observed HI was 298. 
| DISCUSSION
The interference of HL is a main concern in laboratory medicine and could result in positive or negative bias in the measurement of various analytes. 13 HL may occur already in vivo, eg, by increased fragility of erythrocytes due to inherited disorders, but is more common in the pre-analytic stage during or after blood withdrawal. Especially in the pediatric setting, HL is often caused by squeezing during blood withdrawal. Other causes of in vitro HL are mechanical destruction during sample transport or procession. 14 Typical analytes, the measurement of which is affected by HL, are lactate dehydrogenase, potassium, and some tumor markers which are released from erythrocytes. In the modern laboratory, free hemoglobin can be determined in minimal sample volumes simultaneously with multiple analytes. This also offers the possibility to study the influence of HL on immunodetection of IgA-aTTG in more detail.
Tissue transglutaminase is abundant in red blood cells. Its content in erythrocytes exceeds that in other cell types. 8 Red blood cell TTG 15 is released after lysis of erythrocytes and competes with recombinant TTG coated to the plastic surface or to beads of the test kits. In a publication, which is unfortunately payed relatively little attention to by gastroenterologists and clinical chemists, it was recently shown that visible free hemoglobin interferes with measurements of IgA-aTTG.
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However, in clinical routine this source of diagnostic invalidity is not generally considered.
Here, we re-investigate the role of HL in detection of IgA-aTTG.
We confirm the finding that the IgA-aTTG assay is affected by HL in dependence on the concentration of free hemoglobin. In addition, we are able to show that the initial concentration of IgA-aTTG in the sam- We observed marginal differences between assay A and B. These differences were found not only in sera with low-positive IgA-aTTG F I G U R E 4 Proposal for interpretation of IgA-antibodies against tissue transglutaminase (IgA-aTTG) concentration in the context of hemolysis (HL). The scheme is based on test results with assay A in Figure 1 (visualized by the filled black circles). In the white area, there is no diagnosis-relevant influence of HL on the concentration of IgA-aTTG. In the gray area, HL may cause -in dependence on the HL index (HI) -a decrease in the concentration of IgA-aTTG below the borders of 1 × ULN or 10 × ULN, which are relevant for celiac disease diagnosis. Note that in both, the white and the gray areas, HL may reduce IgA-aTTG levels relevant for the assessment of the compliance of gluten-free diet. No sera with HI >300 were found in our study concentrations but also in samples with higher values. The differences may be explained by varying analytical sensitivities of the 2 tests 3, 16 leading to a rearrangement of samples in our groups for different IgA-aTTG concentrations (see numbers in the right upper corner in Figure 1 ). Therefore, assay B seems less affected by HL in the group of samples which show low IgA-aTTG values. We speculate that falsepositivity observed in 1 or 2 sera applying assay A or B, respectively, is due to binding of unspecific patient's antibodies to components of the blocking reagents used in the tests. A possible procedure to identify false-positive samples might be the addition of hemolyzed blood.
Until now, we only had the chance to investigate these 2 samples and further evaluations of these findings are needed.
We assume that HL does not only influence the IgA but also the IgG-class of aTTG. IgG-aTTG is sometimes used for diagnostics in case of IgA-deficiency. The effect of HL on IgG-aTTG remains to be investigated.
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